SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is trending as investors grapple with a significant disconnect between record-breaking quarterly financial performance and a suppressed stock price. The community is actively debating whether the current price action is driven by institutional manipulation, sector-wide consumer softness, or concerns regarding brand cannibalization and competitive pressure from rivals.

Twin Vee PowerCats Co. engages in the design, manufacture, and sale of recreational and commercial power catamaran boats. The firm is focused on designing and developing its products under the ELECTRA Power Sports brand. It operates through the Twin Vee PowerCats and Wizz Banger, Inc. Segments. The Twin Vee PowerCats segment designs, manufactures, and sells recreational and commercial powerboats. The Wizz Banger, Inc. segment refers to a development-stage subsidiary with plans to develop an innovative online marketplace leveraging artificial intelligence (AI) to transform how customers search for and purchase recreational marine assets. The company was founded by Roger Dunshee in 1996 and is headquartered in Fort Pierce, FL.

Twin Vee PowerCats Co

Twin Vee PowerCats is seeing significant retail interest driven by its ultra-low micro-float status and momentum following a reverse stock split. The community is actively discussing the stock's squeeze potential, drawing comparisons to other high-volatility runners and pointing to recent insider buying as a catalyst for a potential parabolic move.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, which confirmed a clear regulatory path toward a late-2026 BLA submission with potential priority review. Community discourse is heavily focused on the company's best-in-class label potential, strong cash position through 2027, and anticipation of upcoming Phase 3 trial data readouts.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is experiencing a volatile surge driven by intense retail and institutional momentum, as traders draw parallels to the recent multi-week squeezes in larger memory sector peers. Investors are actively discussing the stock's potential as a low-float, high-upside play within the Edge AI and defense-infrastructure space, with many anticipating further upside despite discussions regarding legal challenges and valuation.

Applied Digital Corporation

Applied Digital is trending as investors capitalize on massive AI infrastructure expansion and institutional interest, with the community actively debating whether to hold through potential volatility or lock in gains. Traders are closely monitoring upcoming sector earnings for potential ripple effects, while long-term shareholders remain focused on the company's substantial contracted lease pipeline.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors debate the timing of long-awaited Phase 3 data for its leukemia candidate, with the community actively split between concerns over trial delays and optimism regarding potential curative efficacy and institutional positioning. The core discussion centers on the lack of an announced 80th event as a sign of durable patient survival versus frustration over the companys silence and repeated requests for stock-based compensation.

Odysight.ai, Inc. engages in the development and manufacture of customized visual solutions for organizations across a variety of industries in the form of micro cameras and supplementary technologies. Its devices can used across the medical, aerospace, industrial, research, and defense industries. The company was founded on March 22, 2013 and is headquartered in Omer, Israel.

Odysight.ai Inc

Odysight.AI Inc

Odysight.AI is currently capturing significant community attention following a cooperative research agreement with the U.S. Navy for AI-driven visual sensing technology. While bulls are excited by the potential for defense-sector growth and momentum, many traders are actively debating the sustainability of the price action and expressing skepticism regarding corporate dilution and past performance.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is facing heightened volatility and selling pressure following a revenue guidance miss, as investors weigh strong earnings beats against broader concerns regarding AI disruption in the enterprise SaaS sector. While many community members view the sharp price drop as a disconnect from the company's growth and cash-rich balance sheet, others remain cautious, debating whether established software platforms can effectively pivot or if they are vulnerable to emerging agentic AI competition.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust is capturing significant investor attention as market participants debate whether silver is entering a long-term breakout cycle driven by rising industrial demand and supply chain concerns. Community sentiment is deeply divided, with many traders actively discussing potential short squeezes and hedging strategies while others remain skeptical about the sustainability of current price action amidst broader macroeconomic volatility.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, United Online (UOL), and Consumer Products. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Lingo segment offers a global cloud or unified communications and managed service provider to Enterprise and Small to Medium Businesses in the United States. The magicJack VoIP segment is a non-interconnected Voice-over-IP (VoIP) cloud-based communications service provider that offers related devices and subscription services within the United States and Canada. The Marcon segment is a mobile virtual network operator that provides mobile phone voice, text, and data services and devices using the Credo Mobile brand. The United Online segment is an Internet access provider that offers dial-up and digital subscriber line services under the NetZero and Juno brands across the United States. The Consumer Products segment generates revenue through sales of laptop and computer accessories. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors monitor a potential turnaround, fueled by ongoing strength in its key equity holdings like Babcock & Wilcox and Applied Digital. The community is actively discussing the stock's significant short interest and the potential for a massive upside re-rating as the company clears debt and navigates upcoming quarterly earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company’s recently filed 10-Q filing satisfied Nasdaq’s quarterly reporting requirement.</li><li>The company failed to report its results for the quarter ended Sept. 30 in a timely manner, resulting in noncompliance with Nasdaq's Listing Rules.</li><li>The company filed its third quarter earnings report last week, posting a 28% jump in revenue for the period.</li></ul>Laser Photonics shares (<a href="https://stocktwits.com/symbol/LASE">LASE</a>) jumped more than 3% in premarket trading on Wednesday after it regained compliance with Nasdaq listing rule 5250(c)(1) regarding the timely filing of periodic reports.The Nasdaq Stock Market confirmed that the company's December 23 filing of its Form 10-Q for the quarter ended September 30, 2025, satisfied the quarterly reporting requirement. Nasdaq has closed the related compliance matter.The company received a notice from Nasdaq’s listing qualifications department in November stating that, because it had not received Laser Photonics’ Form 10-Q for the period ended September 30, 2025, it does not comply with Nasdaq's Listing Rules for continued listing.Nasdaq had stated that the company has until January 19, 2026, to submit a plan to regain compliance with respect to the delinquent report.Nasdaq may grant an exception to allow the company to regain compliance for up to a maximum of 180 calendar days from the Form 10-Q due date.&nbsp;<h2 class="st-heading-2">Q3 Results</h2>The company last week filed its third quarter (Q3) earnings report, which showed a 28% jump in total revenue to $0.9 million, up from $0.7 million the year-ago period.&nbsp;"Our Q3 report was impacted by a number of expense items and when combined with acquiring Beamer, caused us to be late with our quarterly filing. As this is now resolved, we expect to be back in compliance with Nasdaq imminently,” Carlos Sardinas, Chief Financial Officer of Laser Photonics, said.&nbsp;The Orlando-based company develops industrial laser systems for cleaning and material processing applications. The company has expanded its operations through acquisitions of Beamer Laser Systems and Control Micro Systems, broadening its capabilities into pharmaceutical and semiconductor manufacturing markets.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around LASE trended in “bearish’ territory amid “low” message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:776/74;" src="https://news.stocktwits-cdn.com/LASE_PNG_3aa61b8267.webp" alt="Retail sentiment around LASE trended in “bearish’ territory amid “low” message volumes. " width="776" height="74"></figure>Shares in Laser Photonics have fallen 61% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Blue laser light shines in a part of an optical clock in a laboratory at the Physikalisch-Technische Bundesanstalt (PTB) in Braunschweig, Germany. (Photo by Julian Stratenschulte/picture alliance via Getty Images)

What’s Behind Laser Photonics' Stock Rise Today?

After months of regulatory scrutiny, Laser Photonics regained Nasdaq compliance. 

Equity

Laser Photonics (NASDAQ:LASE) Announces Quarterly Earnings Results

Laser Photonics (NASDAQ:LASE - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($1.09) earnings per share for the quarter. The company had revenue of $0.92 million...

Laser Photonics (NASDAQ:LASE) Stock Price Down 2.9% - Here's What Happened

Laser Photonics (NASDAQ:LASE) Shares Down 2.9% - Time to Sell...

Laser Photonics (NASDAQ:LASE) Trading Down 3.3% - Here's Why

Laser Photonics (NASDAQ:LASE) Trading Down 3.3% - Time to Sell...

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Laser Photonics Corp. engages in the business of manufacturing and research and development of industrial laser technologies and systems. The firm also offers operations that allow the customers to reduce development and advanced laser equipment manufacturing time, offer better prices, control quality, and protect the proprietary knowhow and technology compared to other laser cleaning companies and companies with competing technologies. The company was founded on November 8, 2019 and is headquartered in Orlando, FL.

Current Price	$0.8468
Prev Close	$0.8731
Open	$0.8674
Dividend Yield	0.00%
50-Day Moving Average	$0.9521
Beta	1.43
Avg. Volume	2.37M
PE Ratio	-0.49

52-Week High	$6.77
52-Week Low	$0.38
Market Capitalization	$28.47M
EPS (Annual)	-$1.90
Price to Book	-3.96
Revenue Per Employee	$88,744.77

LASE
Laser Photonics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LASE News

LASELaser Photonics Corp